… The aim of this study was to evaluate the cost-effectiveness of gefitinib plus chemotherapy
(GCP) versus gefitinib alone for advanced non-small-cell lung cancer (NSCLC) patients with …

… Abstract: This study aims to study the role of gefitinib on patients with advanced … of gefitinib
combined with pericardial perfusion in the treatment of advanced non-small cell lung cancer. …

… clinical trials in advanced/metastatic non-small cell lung cancer. Each study was individually
reviewed and data points … Gefitinib is the first tested EGFR inhibitor in advanced NSCLC. …

… Erlotinib was better tolerated, and its use was associated … (EMA) approved gefitinib for the
treatment of advanced EGFR-… evaluated the use of osimertinib after progression on gefitinib or …

… Gefitinib was compared to chemotherapy as first-line … EGFR mutations treated with gefitinib
had longer mPFS compared to … Older-patient specific data regarding gefitinib is available from …

… Bayesian ranking profiles of comparable treatments on efficacy for patients with advanced
ALK-rearranged, non-small cell lung cancer. The profiles indicate the probability of each …

… The research object of this paper is patients with advanced non-small cell EGFR mutation
positive. After targeted therapy, it falls between first-line therapy and second-line therapy, …

… The comparator used in this analysis was gefitinib. Platinum-based chemotherapy was
excluded as a standard first-line therapy in our study because TKIs have shown a better …

… The activation of the insulin-like growth factor 1 receptor (IGF-1R) seems to be related to
EGFR-TKI resistance as shown in in vitro studies on lung cancer cell lines resistant to gefitinib …

… treatment for lung cancer may increase the risk of prolonged QTc in patients. First, almost all
patients undergoing surgery for lung cancer in this study started to take gefitinib after surgery…